Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial

Background: Darolutamide, an androgen receptor antagonist with a distinct molecular structure, significantly prolonged metastasis-free survival versus placebo in the phase III ARAMIS study in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). In this population, polypharmacy for a...

Descripción completa

Detalles Bibliográficos

Publicado en:	Targeted Oncology Vol. 14; no. 5; pp. 527 - 540
Autores principales:	Shore, Neal, Zurth, Christian, Fricke, Robert, Gieschen, Hille, Graudenz, Kristina, Koskinen, Mikko, Ploeger, Bart, Moss, Jonathan, Prien, Olaf, Borghesi, Gustavo, Petrenciuc, Oana, Tammela, Teuvo L., Kuss, Iris, Verholen, Frank, Smith, Matthew R., Fizazi, Karim
Formato:	research tables/charts randomized controlled trial Journal Article
Publicado:	Springer Nature Oct2019
Acceso en línea:	Ver este registro en EBSCOhost